She has a longstanding interest in developing better treatments for schizophrenia having served on the Board of Karuna Therapeutics prior to their successful acquisition by Bristol Myers Squibb ...

Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approximately $14 billion.